STUDresearch · Peptide
Crystagen
Also known as
EDP peptide · Glu-Asp-Pro · EDP tripeptide · immune bioregulator · Khavinson immune cytogen · Crystagen® (commercial bioregulator branding) · Kristagen · T-38 (designation in some originator/vendor lists) · AC-6 (coded Glu-Asp-Pro in some bioregulator catalogs) · thymus/immune short peptide bioregulator · EDG peptide (conflicting vendor sequence claim — see sequence uncertainty) · EAD peptide (search misspelling / informal shorthand) · Glu-Asp-Gly (alternate vendor sequence discussions; often mapped to Chonluten in originator tissue-pair schemes)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Oral / Lingual / SubQ
Longevity & bioregulators
Systemic immune/thymus bioregulator framing; not a local soft-tissue or injury-site injection.
What people say
Crystagen is usually identified as synthetic Glu-Asp-Pro (EDP), a 359.33-Da immune/thymus tripeptide related to the Thymalin lineage. It is not the multi-fraction Thymalin extract, and EDG labels create a real identity conflict.
Doses people talk about
Capsules, lingual products, isolated EDP research material and Thymalin extract are not bioequivalent; EDG/EDP identity conflict further limits comparisons.
How it may feel
The product-specific community picture is exceptionally thin. One long-time peptide user gave only a vague positive/no-bad-reaction account; a more detailed multi-thymic stack produced no significant lymphocyte change at a two-month retest. Neither establishes an acute felt effect.
Oral intensive calendar2 capsules once daily for ~30 days; some tables say ~200–400 mcg per capsule
Peptide mass is brand-dependent and often not independently disclosed.
Oral short or maintenance block1–2 capsules daily for ~10–20 days; sometimes 2 daily for ~10 days every ~3 months
Retail maintenance calendar, not a PK-derived interval.
Alternate oral label1–2 capsules, 1–2 times daily for ~1 month
Some Eastern retail inserts pair this with meals and repeat after ~4–6 months.
Injectable research chart~1,000–2,000 mcg once daily SubQ
Repeated English vendor/community handling band, not an approved clinical regimen.
Alternate injectable notes~0.5–1 mg daily; one catalog lists ~1.6 mg
Outlier community/vendor material, including a nonstandard sequence claim; not consensus.
Parent Thymalin contrast~10 mg IM daily for ~5–10 days
Historical multi-fraction extract context only; orders of magnitude and product identity differ from isolated EDP.
Cell-culture research~10⁻⁷ to 10⁻¹² M
In-vitro concentrations only; they do not map to a human capsule or injection amount.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- One multi-peptide accountPositive experience without bad reactions
- Another stacked-use accountNo significant lymphocyte change at a 2-month follow-up
- Felt durationNo consistent window reported
Cycles people discuss
Preserved calendars include 10–20-day pulses, 20–30-day oral intensives and periodic boosters, sometimes followed by Vladonix. These are product-culture schedules, not human PK-derived cycles.
Timing
Retained product/community timing differs by form: oral use is often with or before meals, lingual schedules follow the drop insert, and injection discussions commonly use a consistent daily time. Fed versus empty-stomach claims are not settled timing evidence.
Stacks
Vladonix, Vilon, Thymogen, Thymalin and Epitalon appear in immune/longevity rotations. A detailed null report combined several thymic agents, so its two-month lab result cannot isolate Crystagen.
Watch for
Gray-market / identity risk: Mislabel (EDG vs EDP vs wrong tripeptide), underdose, contamination, endotoxin, and non-sterile injectable handling are primary practical hazards.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A product-specific human half-life, oral bioavailability and tissue-distribution profile for isolated EDP Crystagen were not established in the reviewed material.
The patent defines H-Glu-Asp-Pro-OH and parenteral experimental/clinical contexts but supplies no concentration-time curve. A transporter review discusses ultrashort-peptide carrier models rather than Crystagen human PK.
Bounded review of the patent, an open transport review and accessible community records; this does not prove global absence. Form, salt, route and EDG/EDP identity conflicts further limit inference.
- US8057810B2 — Peptide substance revealing an immunogeroprotective effect (opens in a new tab)Definitions and claims identify H-Glu-Asp-Pro-OH (EDP); patent PDF states molecular weight 359.33. Examples cover animal, cell and small clinical contexts but no concentration-time PK curve.Patent from the originator line, not independent efficacy confirmation or a modern regulatory PK package; claims and examples do not establish current commercial-product identity.
- Khavinson et al. — Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers (opens in a new tab)Tables identify Crystagen as EDP and discuss predicted/experimental transporter interactions for ultrashort peptides; no Crystagen human concentration-time or half-life study is presented.Originator-line mechanistic review with transporter models and heterogeneous peptides; it cannot supply product-specific human PK or oral exposure.
Felt duration people report
The sparse product-specific reports do not establish an acute onset, a per-dose felt window or a reproducible post-course duration.
One six-year multi-peptide user described Crystagen only as positive and without bad reactions. A separate user combined Crystagen 1–2 mg with Vilon, Thymogen, Thymulin and TA-1 and found no significant lymphocyte change on a second test two months later.
The positive account has no Crystagen dose, endpoint or isolated course; the null account is multi-agent and its two-month laboratory checkpoint is not a felt-duration measurement.
- Long Covid Brain Fog/Damage? — Crystagen user follow-up (opens in a new tab)Comment and same-author reply: called oral peptides effective and Crystagen the preferred thymus-support product; later said six years of using various peptides including Crystagen produced no bad reaction and only positive results.No Crystagen-specific dose, course, route confirmation, objective endpoint or time-to-effect; six years involved multiple peptides and cannot establish safety or efficacy.
- Some research results to share — Crystagen multi-agent laboratory null (opens in a new tab)Post lines describing Vilon 1–3 mg, Thymogen 50 mcg, Thymulin about 0.3 mg and Crystagen 1–2 mg; a detailed immune-panel retest two months later showed no significant lymphocyte change.Single unverified multi-agent experiment, products and adherence not independently verified; the two-month result cannot isolate Crystagen or define acute felt duration.
What people say
- Seasonal / infection-frequency resilience (community): Steadier cold seasons or fewer lingering mild infections after courses—highly confounded by sleep, training load, co-stacks, and selection bias. forumanecdote
- Post-stress / athletic immunity (originator summaries): Oral crystagen combined with other short peptides described as increasing stress resistance and normalizing immunity in athletes; single-agent credit unreliable. trialforum
- Cytogen starter role: Often the short synthetic immune course before longer Vladonix-style natural thymus complexes (Cytogen → Cytomax sequencing lore). forum
- Feel: Little-to-no acute “kick,” mood lift, or stimulant-like signal; judgments are later illness-frequency or lab-marker notes if anything. forumanecdote
- Spleen / B-cell (aging models): Organotypic spleen work reports Crystagen activates B-cell markers (e.g., CD20 expression area increases in originator tables) while other short peptides (Vilon, R-1) preferentially moved T-helper compartments by different routes; Crystagen did not restore cellular renewal processes in aging spleen the way some comparators claimed. animallab
- T-cell immunogram talk (observational lineage): Originator clinical-era summaries cite increases in CD3+ and CD4+ counts and CD4+/CD8+ ratio normalization; one often-repeated figure is immunogram normalization in ~82% of subjects vs ~56% on standard care—small non-Western observational context, not a modern multi-center RCT of isolated EDP. trial
- Selective lymphocyte vs tumor-cell proliferation (in vitro): Originator work describes enhanced spontaneous proliferative activity of normal human lymphocytes with concurrent inhibition of K-562 erythromyelosis cell proliferation—hypothesis-level selectivity, not an oncology protocol. lab
- Cytokine / macrophage signaling (preclinical): Stimulatory effects on peritoneal macrophage cytokine output (IL-1, IL-6, TNF-α cited in young and old mouse preparations) and monocyte/macrophage pathway modulation in THP-1-type models—framed as regulation, not pure “boost.” labanimal
- Thymic radioprotection (animal): In gamma-irradiated rats, Crystagen-associated preservation of cortex–medulla architecture, thymocyte proliferation, and higher macrophage/mast-cell counts is reported as immunogeroprotective in an accelerated-aging model. animal
- Immunosenescence framing: Positioned for age-related immune decline and thymus involution narratives—not as treatment for diagnosed immunodeficiency, HIV, transplant rejection, or acute viral disease. forumtrial
- What it is not proven for: Infection prophylaxis, autoimmune disease therapy, cancer treatment, vaccine non-response rescue, or any FDA-labeled indication. trial
- Thymic epithelial / microenvironment (cell models): EDP reported to stimulate proliferation of human thymic epithelial cell lines (e.g., VTEC2.H/S framing)—used to argue support for the niche that educates T cells during involution, not acute thymic regeneration imaging in humans. lab
Doses people talk about
- Oral capsules — short / maintenance: ~1–2 capsules daily for ~10–20 days; common maintenance is ~2 capsules daily for ~10 days every ~3 months after an intensive block. forum
- Oral capsules — alternate vendor wording: ~1–2 capsules, 1–2 times daily with meals for ~1 month, repeat every ~4–6 months (some Eastern retail inserts). forum
- Oral timing talk: Often morning or with/before meals; some multi-bioregulator guides say take with food except a few non-immune products (Endoluten/Glandokort/Bonothyrk exceptions in brand guides—not Crystagen-specific PK). forum
- Injectable research-chem charts (lyophilized vials, usually 20 mg): ~1,000–2,000 mcg once daily SC is the most-repeated handling band on English research-protocol pages. forum
- Alternate injectable community notes: Some longevity-stack writeups mention Crystagen in a ~0.5–1 mg daily band alongside Epitalon courses; another catalog-style page lists ~1.6 mg (with a nonstandard sequence claim)—treat as outlier vendor variance, not consensus. forum
- Course frequency: Often ~2–4 courses/year (short oral blocks) or ~2–3× yearly in research-facing oral tables; intensive 30-day courses may be repeated with at least ~1 month rest, with some brand guides capping aggressive re-intensives (e.g., max ~5 full intensives/year discussed for bioregulators generally). forum
- Cytogen → Cytomax sequencing math: Common lore is Crystagen (synthetic cytogen) ~1 month, then Vladonix (natural thymus cytomax) ~2 months for “deeper” multi-peptide complex exposure—ratios/brands of Vladonix vary; not a fixed pharmacy compound. forum
- Uncertainty / non-interchangeability: Capsules, lingual drops, and research vials are not bioequivalent; EDG vs EDP labeling, underdose, and mislabel are structural gray-market risks; oral intact-tripeptide bioavailability lacks independent modern PK. forumtrial
- Oral capsules — intensive (consumer bioregulator pattern): ~2 capsules once daily for ~30 days (often ~60 capsules / three 20-cap boxes in Nature’s Marvels-style calendars). Peptide mass per cap is brand-dependent; some research-facing tables quote ~200–400 mcg active per capsule dose band, while many retail labels only say “peptide complex” without third-party mcg disclosure. forum
- Parent extract contrast (not Crystagen dose): Clinical-era Thymalin protocols often cite ~10 mg IM daily for ~5–10 days (sometimes repeated annually)—orders of magnitude different mass and a multi-fraction product; do not copy Thymalin mg charts onto EDP vials. trial
- In vitro concentrations (not human doses): Cell-culture papers use roughly 10⁻⁷ to 10⁻¹² M ranges—useless for syringe math, listed only to mark how far preclinical work sits from consumer capsules. lab
- Framing: Community, vendor, and originator-summary ranges only — not advice, prescriptions, or safety-validated protocols. No modern Western dose-ranging RCT establishes a human therapeutic dose of isolated Crystagen. forumtrial
How it may feel
- Days 1–3: Little acute change expected; mechanism is not acute receptor stimulation. Oral users typically report no “on” feeling; injectors mainly notice needle/site awareness. Same-day energy claims are anecdotal and confounded. forumanecdote
- Days 4–10 (classic pulse window): Many short Khavinson-style oral or research inject courses run here. Subjective logs stay mostly neutral; closest anchors remain preclinical or delayed resilience claims, not felt endpoints. forum
- Days 10–20 / end of short oral course: Common stop window for 10–20 day capsules or lingual blocks. Some claim steadier baseline energy or fewer “on the edge of a cold” days—causality weak without exposure tracking. forumanecdote
- Day 20–30 (extended oral intensive): Consumer bioregulator calendars often push a full ~30-day “intensive” at 2 capsules/day; still not a stimulant timeline. forum
- Weeks 2–8 post-course: Bioregulator lore expects residual “aftereffect” weeks after the peptide is gone (gene/immune signaling narrative)—not proof of long plasma residence. Any residual benefit is framed as post-burst, not continuous blood levels. forumanecdote
- Months 3–6: Re-run culture is seasonal or scheduled (~2–4× yearly / every 3–6 months maintenance 10-day boosters), not open-ended daily for years without breaks. forum
- Vendor 8–12 week injectable charts: Some research-chem protocol pages extend SC titration for weeks 3–12 at ~2,000 mcg/day—this is longer than classic originator short-course culture and is not backed by independent dose-finding trials; treat as lab-handling charts, not validated therapy. forum
- No change after 1–2 courses: Community re-checks sleep, training/illness load, oral vs injectable product identity, EDG vs EDP label confusion, and whether the goal (infection count vs longevity markers) matches a short bioregulator pulse—not automatic mega-dose. forum
Cycles people discuss
- Classic short bioregulator pulse: ~10–20 consecutive days on, then weeks-to-months off—the pattern most aligned with originator short-peptide culture. forumtrial
- Extended oral intensive: ~20–30 day capsule or calendar courses (2 caps/day intensive is the retail default). forum
- Maintenance after intensive: ~10 days on (often 2 caps/day) every ~3 months; after multi-year use some brand guides taper to ~10-day boosters every 6–12 months. forum
- Then thymus complex: Common calendar is Crystagen month → longer Vladonix-style natural thymus complex phase (~2 months in cytogen→cytomax lore). forum
- Seasonal / post-illness re-runs: Courses timed before winter, travel, or after prolonged illness—attribution remains confounded. forumanecdote
- Multi-organ rotations: Immune leg rotated with vessel (Vesugen/Ventfort), pineal (Epitalon/Endoluten/Pinealon), cartilage, liver/GI cytogens; brand guides often cap ~5 new bioregulator types per month when stacking many organs. forum
- Injectable research courses: Short multi-week daily SC blocks appear in vendor charts; some extend to ~8–12 weeks—longer than classic lore and thinner on independent outcome data. forum
- Not year-round daily forever: Open-ended daily use without off periods is not the classic Khavinson calendar; multi-year gray-market safety databases for isolated EDP are not established. forumtrial
- Rest between intensives: At least ~1 month rest between full 30-day intensives is commonly advised in consumer bioregulator guides when repeating aggressively. forum
Timing
- Legacy timing talk: The preserved profile repeats hours-scale action and once-daily-course conventions rather than multi-day depot logic, but the reviewed transporter literature does not establish Crystagen-specific human PK or plasma duration. forum
- Why short courses: Practice culture + gene-expression / “aftereffect” narratives, not long plasma half-life. Claimed immune steadiness for weeks after stopping ≠ peptide still circulating. forumanecdote
- Timing defaults: Oral 1–2× daily with/before meals; lingual multiple times daily per drop inserts; research injectors usually once daily same clock time. Empty-stomach vs fed debates are not settled by controlled timing trials. forum
- PK gap: No formal modern human pharmacokinetic package (half-life, bioavailability, tissue distribution) for isolated Crystagen/EDP in open Western sources. trial
- Proline note (theoretical): C-terminal proline is sometimes argued to slow certain carboxypeptidases relative to non-proline endings—still not a published human t½ for EDP. trial
- Oral vs inject exposure: Injectable Thymalin extract history does not prove oral capsule EDP reaches lymphoid tissue at active concentrations; independent intact-tripeptide oral bioavailability is poorly characterized. trial
- In vitro ≠ in vivo kinetics: Nanomolar–picomolar culture exposures over 24–72 h do not map to capsule or syringe schedules. lab
More on what it is
- What it is: Synthetic Glu-Asp-Pro (EDP) tripeptide in the Khavinson immune/thymus bioregulator line. The reviewed patent identifies H-Glu-Asp-Pro-OH and a molecular weight of 359.33 Da; some commercial pages instead list EDG, so sequence identity remains a practical concern. trialforum
- Why people search it: Oral immune cytogen next to Vladonix, Vilon, Thymalin, and Epitalon longevity calendars; milder “course then rest” culture than daily injectables like BPC or GLP-1s. Far less forum volume than those compounds. forum
- Sequence uncertainty: EDP (Glu-Asp-Pro) is the dominant research/catalog identity for Crystagen; EDG (Glu-Asp-Gly) is often paired with bronchial bioregulator Chonluten in tissue-specificity schemes. Vendor COAs and labels still disagree—identity testing matters more than brand name. forumtrial
- Lens for logs: Benefits framed as delayed immune-resilience metrics after short courses, not day-one stimulation. Stacks, sleep, illness exposure, and product purity dominate self-reports. forum
- Thymalin pedigree: Originator reviews present EDP as one of three principal short bioactive fractions identified from bovine thymus extract Thymalin (alongside KE/Vilon and EW/Thymogen). Synthetic Crystagen is the single-sequence stand-in for that EDP motif—not the multi-fraction extract itself. trial
- Mechanism talk (proposed): Ultrashort peptide → cell/nuclear entry → DNA/histone contact → rebalance of immune-related gene programs (T/B cells, cytokines, thymic epithelial support). Western molecular biology treats sequence-specific nuclear DNA-binding by a bare tripeptide as an extraordinary, under-replicated claim. labtrial
- Evidence honesty: Almost entirely one research lineage (Khavinson/Linkova and collaborators); Russian-language and affiliated journals dominate. Sparse independent Western RCTs of isolated Crystagen; parent Thymalin has more clinical-era history but multi-component effects cannot be attributed to EDP alone. trial
- Not the same as: Not Thymosin Alpha-1 (28-aa TLR-pathway peptide with broader international clinical history); not Thymalin extract (multi-fraction); not Thymogen (EW) or Vilon (KE); not a steroid, vaccine, or FDA-approved immune drug. trial
Stacks
- Crystagen → Vladonix (cytogen → cytomax): Most-cited immune sequencing—synthetic short course first, then multi-peptide natural thymus complex for a longer phase; ratios/brands of Vladonix vary. forum
- + Epitalon / pineal leg: Paired with Epitalon (sometimes Pinealon or Endoluten) in longevity calendars (pineal + thymus “first class” style stacks). forum
- + Vilon (KE) and/or Thymogen (EW): Stacked or compared as the other Thymalin-derived short sequences—attribution of any single-agent effect gets muddy fast. forumtrial
- + Thymalin extract: Some users alternate or layer the multi-fraction injectable/historical product with synthetic cytogens—do not assume dose or effect equivalence. forum
- Multi-organ rotations: With vessel (Vesugen/Ventfort), cartilage (e.g., Cartalax/Sigumir talk), liver/GI (Ovagen etc.), bone marrow (Bonomarlot) in full-body bioregulator programs. forum
- Vs Thymosin Alpha-1 stacks: Occasional “thymic peptide” shopping comparisons; different molecule, mechanism claims, and evidence tier—not interchangeable. forumtrial
- Lifestyle confounders often co-credited: Sleep, lower infection exposure, vaccines where indicated, nutrition, and deload from overtraining. forum
- Attribution warning: Multi-bioregulator months make it nearly impossible to credit Crystagen alone in anecdotes. anecdote
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Low acute chatter: Few dramatic adverse-event threads for oral cytogen capsules—limited systematic monitoring, not proof of long-term safety. forum
- Injection site: Mild redness, itch, swelling, or tenderness with SQ research injectables—technique and sterility dependent. forum
- Early nonspecific (sparse): Headache, transient fatigue, or mild GI unease appear in occasional anecdotes—causality unclear vs concurrent illness or stacks. anecdote
- Immune stimulation caution: Autoimmune disease, organ transplant, active immunotherapy/checkpoint inhibitors, or uncontrolled inflammatory disease users discuss extra medical supervision—theoretical risk of worsening autoimmunity or graft issues is not ruled out by dedicated trials. forumtrial
- Gray-market / identity risk: Mislabel (EDG vs EDP vs wrong tripeptide), underdose, contamination, endotoxin, and non-sterile injectable handling are primary practical hazards. forum
- Route inequivalence: Capsule mg, drop mL, and vial mcg are not interchangeable; copying Thymalin 10 mg IM charts onto Crystagen is a category error. forumtrial
- Quiet sides ≠ purity or efficacy: Absence of loud side-effect threads does not validate product identity, sterile manufacture, or clinical benefit. forum
- Malignancy context: In-vitro selectivity (normal lymphocytes up / K-562 down) is not a green light for self-experimentation in cancer; oncology decisions need licensed care. labtrial
- No formal gaps list (honest): Dedicated isolated-EDP toxicology, MTD, PK, drug-interaction, pregnancy, and autoimmune-safety studies are largely missing from open literature. trial
- Originator “well tolerated” framing: Parent Thymalin described as practically non-toxic across decades of Russian clinical use; that does not equal a modern isolated-EDP toxicology package, Western PV database, or FDA safety review. trial
- Not treatment / not prophylaxis: Not FDA-approved for infection prevention, immunosenescence therapy, or any disease indication; research and educational framing only. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.